Beam Therapeutics Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Beam Therapeutics Inc. (BEAM) reported initial data from its Phase 1/2 trial of BEAM-301 for glycogen storage disease type Ia. Two patients in the 40 mg cohort achieved 15 hours of controlled fasting. All patients experienced adverse events, with four having serious events. The company plans to engage with the FDA regarding a potential approval pathway.
Evans John M. (CEO) sold 50,000 shares of Beam Therapeutics Inc. (BEAM) at an average of $23.77 ($23.57–$23.98, $1.19M total) across 2 trades over 2026-10-15 to 2026-10-16 under a Rule 10b5-1 trading plan.
HC Wainwright & Co. reiterated a Buy rating on Beam Therapeutics with an $80 price target, implying a 238.3% upside from the Oct 14 close of $23.65. The rating is based on positive Phase 1/2 trial results for BEAM-301, showing efficacy in treating glycogen storage disease type 1a, and confidence in the company's liver-directed delivery platform.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning BEAM (Beam Therapeutics Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent BEAM coverage spans financial news, technology and regulation.
In the last 30 days, BEAM insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($1.2M). The most active reporter was Evans John M., CEO, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Early trial shows efficacy in higher dose cohort with extended fasting times, but safety signals remain.
The insider sale may signal confidence concerns and could pressure the stock lower in the short term.
Positive trial data is likely to drive buying interest in BEAM.
Positive early trial data may lift sentiment and attract speculative buying.
Fund endorsement likely drives short-term buying pressure.
AlphAI scores every news story that mentions BEAM with an AI model for sentiment and relevance, and aggregates insider trades from Beam Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Beam Therapeutics Inc. (BEAM) reported initial data from its Phase 1/2 trial of BEAM-301 for glycogen storage disease type Ia. Two patients in the 40 mg cohort achieved 15 hours of controlled fasting. All patients experienced adverse events, with four having serious events. The company plans to engage with the FDA regarding a potential approval pathway.
2 min readEvans John M. (CEO) sold 50,000 shares of Beam Therapeutics Inc. (BEAM) at an average of $23.77 ($23.57–$23.98, $1.19M total) across 2 trades over 2026-10-15 to 2026-10-16 under a Rule 10b5-1 trading plan.
1 min readHC Wainwright & Co. reiterated a Buy rating on Beam Therapeutics with an $80 price target, implying a 238.3% upside from the Oct 14 close of $23.65. The rating is based on positive Phase 1/2 trial results for BEAM-301, showing efficacy in treating glycogen storage disease type 1a, and confidence in the company's liver-directed delivery platform.
1 min readBeam Therapeutics (BEAM) reported early Phase 1/2 trial data for BEAM-301, a gene therapy for GSDIa, showing dose-dependent improvements in fasting hypoglycemia and reduced starch intake. The trial enrolled six patients, with median follow-up of 313 days for the 20 mg cohort and 53 days for the 40 mg cohort. All patients experienced adverse events, but no serious safety concerns were reported. The company will discuss the data at an investor event on October 27.
2 min readBeam Therapeutics (BEAM) shares rose after Cathie Wood's Ark Invest increased its stake by 534,000 shares, citing confidence in its base-editing tech. The company faces risks due to heavy cash burn and ongoing losses, but has a strong pipeline in genetic diseases and cancer. Wells Fargo reiterated a Buy rating.
1 min readWandercraft acquired Ekso Bionics to form a global medical exoskeleton company. Automation Anywhere agreed to buy Boost.ai for conversational AI. Beam Global will acquire ScoutDI for $24M to expand drone tech. Altaris completed a $600M deal for Clarivate's healthcare business.
2 min readBeam Therapeutics (BEAM) sued YolTech Therapeutics and Serapha Bio, claiming they used stolen trade secrets to develop a drug. Serapha Bio recently merged with Boundless Bio (BOLD).
1 min readModerna appointed Juan Andres as its new COO to support expansion into oncology. Pierre Fabre and Atara refiled Ebvallo for FDA approval to treat a rare blood cancer. Beam Therapeutics sued a Chinese company, alleging IP theft by a former scientist.
2 min readBeam Therapeutics (BEAM) filed a lawsuit against a former scientist, YolTech Therapeutics, and Serapha Bio, alleging theft of trade secrets related to gene editing research. The case could impact investor views on Beam's intellectual property, competitive positioning, and legal risks. The company reported a loss of $66.0 million, with analysts projecting earnings of $39.3 million by 2029 and revenue growth of 8.1% annually.
3 min readBeam Therapeutics sued former scientist Emma Wang, alleging she stole trade secrets to found Chinese startup YolTech, which is developing a rival treatment for AATD. Beam claims Wang used stolen information to file patents while still employed. YolTech later licensed its treatment to Serapha.
2 min read
